Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770545 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
A Phase 3 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 792
- Enrollment target
NCT04770545: Completed Phase 3 study, sponsored by Apellis Pharmaceuticals.
NCT04770545 is a Phase 3 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 792 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04770545, a Phase 3 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 792 participants
- Enrollment target
Study Summary
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).
Interventions
- DRUG PEGCETACOPLAN (APL-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 792 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2025-09-05 |
| Phase | Phase 3 |
What the finished NCT04770545 record still lists
NCT04770545 is an interventional study that assigns participants to a tested intervention. The registered 792 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which PEGCETACOPLAN (APL-2) is the first listed.
NCT04770545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04770545 about?
NCT04770545 is a clinical study titled "An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD". This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment ...
What is the current status of trial NCT04770545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 792 participants. The study started on 2021-03-04. Estimated completion is 2025-09-05.
What interventions are being tested in trial NCT04770545?
The interventions under investigation include: PEGCETACOPLAN (APL-2) (DRUG).
Who is sponsoring clinical trial NCT04770545?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04770545's enrollment target sits among peer trials
792 429th of 2000 higher than 1,572 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT05866081 · 792 participants · NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
- NCT06722352 · 792 participants · NA
Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI